Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24393978 | 0.88 | PDE2A (0.37) | SLC6A4SLC6A3PDE2AEPHX2SLC6A2 | |
| SCHEMBL24394104 | 0.85 | THRB (0.37) | SLC6A4SLC6A3PDE2AHDAC3HDAC1 | |
| SCHEMBL24397809 | 0.83 | RORC (0.34) | — | |
| SCHEMBL24397915 | 0.83 | OPRM1 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL24397872 | 0.83 | SLC6A3 (0.39) | SLC6A4SLC6A3PDE2AHDAC3HDAC1 | |
| SCHEMBL24393967 | 0.82 | PDE2A (0.37) | PDE2AEPHX2ALDH1A1 | |
| SCHEMBL24397824 | 0.82 | RORC (0.37) | PDE2A | |
| SCHEMBL24398059 | 0.82 | SLC6A3 (0.41) | SLC6A4SLC6A3PDE2AEPHX2SLC6A2 | |
| SCHEMBL24397743 | 0.81 | DRD2 (0.39) | ALDH1A1 | |
| SCHEMBL24398057 | 0.81 | MAPK1 (0.36) | HDAC3HDAC1HDAC2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| WO-2022090724-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | SLC6A4 4875/4885SLC6A3 4858/4885PDE2A 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.